Peroral formulation of dienogest and ethinylestradiol for contraception

Peroral dosage form for contraception comprises 17 alpha -cyanomethyl-17 beta -hydroxyestra-4,9-diene-3-one (dienogest) (= 2 mg) and 17 alpha -ethinylestradiol (ethinylestradiol) (less than 0.03 mg), where the crystalline active agent dienogest is contained with an average particle size of 30-270 mu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BUSKE, ALEXANDER, LADWIG, RALF, WIESINGER, HERBERT, FRICKE, SABINE, GERECKE, HAGEN
Format:	Patent
Sprache:	eng ; pol
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Peroral dosage form for contraception comprises 17 alpha -cyanomethyl-17 beta -hydroxyestra-4,9-diene-3-one (dienogest) (= 2 mg) and 17 alpha -ethinylestradiol (ethinylestradiol) (less than 0.03 mg), where the crystalline active agent dienogest is contained with an average particle size of 30-270 mu m. ACTIVITY : Contraceptive; Antiseborrheic; Dermatological. MECHANISM OF ACTION : None given.